
    
      PRIMARY OBJECTIVES:

      I. Assessment of neurocognitive function at months 4.

      SECONDARY OBJECTIVES:

      I. Assessment of neurocognitive function at months 2, 6, and 12 as measured by neurocognitive
      decline on a battery of tests.

      II. Assessment of symptom burden, as measured by the M.D. Anderson Symptom Inventory- Brain
      Tumor Module (MDASI-BT).

      III. Assessment of quality adjusted survival and health outcomes using the European Quality
      of Life Five Dimension Five Level scale questionnaire (EQ-5D-5L).

      IV. Assessment of local control, in brain control. V. Assessment of progression free survival
      (PFS), and overall survival (OS). VI. Assessment of side effects and toxicities.
    
  